Aspire Biopharma (NASDAQ: ASBP) has announced the addition of tenured professor, department of medical engineering, University of South Florida, Mark J. Jaroszeski, PhD, to its scientific team.
Dr. Jaroszeski is a leader in the development of DNA/drug delivery technologies and methods to treat disease. He was one of the early pioneers performing in vivo electroporation during the early 1990’s, and was among the first researchers to develop basic electrodes and pulsing protocols to deliver chemotherapeutic agents to tumors in animal models in vivo, safely and effectively, with very strong anti-tumor effects.
In a statement, Kraig Higginson, Interim CEO of Aspire, commented, “Dr. Jaroszeski is recognized globally for his pioneering work in DNA and drug delivery, and we are honored to welcome him to the Aspire team. He brings extensive experience in medical delivery systems that will be instrumental in advancing Aspire’s proprietary sublingual delivery technology. His insight and track record of innovation will play a critical role as we continue to develop and optimize our platform, building on our initial pipeline and extending these benefits to a broader range of generic medicines.”
